Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells

Clinical Cancer Research

Volumn 11, Issue 6, 2005, Pages 2379-2388

  Hu, Hongbo ^a   Jiang, Cheng ^a   Ip, Clement ^b   Rustum, Youcef M ^b   Lü, Junxuan ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANDROGEN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLISOLEUCYLGLUTAMINYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMINYLHISTIDYLASPARTYLFLUOROMETHYLKETONE; CASPASE; CASPASE 3; CASPASE 8 INHIBITOR; CASPASE 9; CASPASE INHIBITOR; DNA FRAGMENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; HISTONE; METHYLSELENINIC ACID; METHYLSELENOL; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; SELENITE; SELENIUM DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; PRECURSOR; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CASPASES; DRUG THERAPY, COMBINATION; ENZYME ACTIVATION; ETOPOSIDE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; ORGANOSELENIUM COMPOUNDS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 16844362028     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2084     Document Type: Article

References (33)

1. American Cancer society: http://www.cancer.org/docroot/stt/stt_0.asp: Cancer facts and figures 2004.
2. Kish JA, Bukkapatnam R, Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control 2001;8:487-95.
3. Klein EA, Kupelian PA. Localized prostate cancer: radiation or surgery? Urol Clin North Am 2003;30:315-30.
4. Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004;10:2561-9.
5. Jiang C, Wang Z, Ganther H, Lü J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001;61:3062-70.
6. Jiang C, Wang Z, Ganther H, Lü J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002;1:1059-66.
7. 1 arrest by selenium metabolite methylselenol. Mol Carcinog 2002;34:113-20.
8. Jiang C, Hu H, Malewicz B, Wang Z, Lü J. Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells. Mol Cancer Ther 2004;3:877-84.
9. Jiang C, Ganther H, Lü J. Monomethyl selenium-specific inhibition of MMP-2 and VGEF expression: implications for angiogenic switch regulation. Mol Carcinog 2000;29:236-50.
10. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000;60:2882-6.
11. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61.
12. Tsao YP, Russo A, Nyamuswa G, Silber R, Liu LF. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 1993;53:5908-14.
13. Taxman DJ, MacKeigan JP, Clements C, Bergstralh DT, Ting JP. Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor. Cancer Res 2003;63:5095-104.
14. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994;5 Suppl 6:S3-6.
15. Scatena CD, Steward ZA, Mays D, et al. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and taxol-induced growth arrest. J Biol Chem 1998;273:30777-84.
16. Costa-Pereira AP, McKenna SL, Cotter TG. Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis. Br J Cancer 2000;82:1827-34.
17. Ghahremani MH, Keramaris E, Shree T, et al. Interaction of the c-Jun/JNK pathway and cyclin-dependent kinases in death of embryonic cortical neurons evoked by DNA damage. J Biol Chem 2002;277:35586-96.
18. 2-terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells. Prostate 2003;55:265-80.
19. Vivo C, Liu W, Broaddus VC. c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 2003;278:25461-7.
20. Wang TH, Popp DM, Wang HS, et al. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem 1999;274:8208-16.
21. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Kishi M, Konishi N. Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis. Carcinogenesis 2004;25:1089-97.
22. Figueroa-Masot XA, Hetman M, Higgins MJ, Kokot N, Xia Z. Taxol induces apoptosis in cortical neurons by a mechanism independent of Bcl-2 phosphorylation. J Neurosci 2001;21:4657-67.
23. 2-terminal Kinase (JNK/SAPK). J Biol Chem 1998;273:28253-60.
24. Cho SD, Jiang C, Malewicz B, et al. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 2004;3:605-11.
25. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-10.
26. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000;92:1042-53. Review.
27. Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 2001;7:95-106. Review.
28. Kirsch DG, Doseff A, Chau BN, et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 1999;274:21155-61.
29. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res 2000;60:1645-53.
30. Chen Q, Gong B, Almasan A. Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis. Cell Death Differ 2000;7:227-33.
31. Park HS, Park E, Kim MS, Ahn K, Kim IY, Choi EJ. Selenite inhibits the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) through a thiol redox mechanism. J Biol Chem 2000;275:2527-31.
32. Park HS, Huh SH, Kim Y, et al. Selenite negatively regulates caspase-3 through a redox mechanism. J Biol Chem 2000;275:8487-91.
33. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.